Drug Profile
Research programme: anticancer therapeutics - Biosceptre International
Alternative Names: Antibody cancer therapy - Biosceptre International; BIL-03s; BIL-04s; BIL-221sLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Arana Therapeutics; Biosceptre International
- Developer Biosceptre International
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Feb 2023 Anticancer therapeutics research programme is still in preclinical phase for Cancer in Australia (Parenteral) (Biosceptre International pipeline, February 2023)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
- 14 Dec 2017 Preclinical development in Cancer is ongoing in Australia (Parenteral)